Advertisement

Gene Therapy for Adenosine Deaminase Deficiency and Malignant Solid Tumors

  • Kenneth W. Culver
  • R. Michael Blaese

Abstract

Gene therapy may be considered the ultimate treatment for genetic diseases (Anderson, 1984). The possibility of reversing genetic defects by replacing the defective gene instead of merely treating symptoms is very appealing. Significant progress in the development of clinical applications of gene therapy has occurred. More than 40 human gene transfer and therapy experiments have been initiated since the introduction of this approach in 1989 (Anderson, 1992; Miller, 1992).

Keywords

Gene Therapy Adenosine Deaminase Bystander Effect Purine Nucleoside Phosphorylase Primary Immunodeficiency Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ammann AJ, Hong R (1989): Disorders of the T-cell system. In Immunologic Disorders of Infants and Children, Steihm ER, ed. Philadelphia. 3rd edition, WB Saunders Co. pgs. 257–315Google Scholar
  2. Anderson WF (1984): Prospects for human gene therapy. Science 226: 401–409PubMedCrossRefGoogle Scholar
  3. Anderson WF (1992): Human gene therapy. Science 256: 808–813PubMedCrossRefGoogle Scholar
  4. Cornetta K, Moen RC, Culver K, et al. (1990): Amphotropic murine leukemia virus is not an acute pathogen for primates. Human Gene Ther 1: 15–30CrossRefGoogle Scholar
  5. Culver K, Cornetta K, Morgan R, et al. (1991a): Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA 88: 3155 - 3159PubMedCrossRefGoogle Scholar
  6. Culver KW, Anderson WF, Blaese RM (1991b): Lymphocyte gene therapy. Human Gene Ther 2: 107–109CrossRefGoogle Scholar
  7. Culver KW, Blaese RM (1992): Gene therapy for immunodeficiency disease. In New Concepts in Immunodeficiency Diseases. Gupta S and Griscelli C (eds). Sussex, UK, Wiley & Sons. pgs. 427–456Google Scholar
  8. Culver KW, Berger M, Miller AD, Anderson WF, Blaese RM (1992a): Lymphocyte gene therapy for adenosine deaminase deficiency. Ped Res 31: 149AGoogle Scholar
  9. Culver KW, Ram Z, Walbridge S, et al. (1992b): In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256: 1550–1552PubMedCrossRefGoogle Scholar
  10. Daddona PE, Mitchell BS, Meuwissen HJ, et al. (1983): Adenosine deaminase deficiency with normal immune function. J Clin Invest 72: 483–492PubMedCrossRefGoogle Scholar
  11. Dunbar C (1992): Personal communicationGoogle Scholar
  12. Elion GB (1980): The chemotherapeutic exploration of virus-specified enzymes. Adv Enz Regulation 18: 53CrossRefGoogle Scholar
  13. Ezzedine ZD, Martuza RL, Platika D, et al. (1991): Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biologist 3: 608–614Google Scholar
  14. Faulds D, Heel RC (1990): Ganciclovir. Drugs 39: 596–638CrossRefGoogle Scholar
  15. Ferrari G, Rossini S, Giavazzi R, et al. (1991): An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251: 1363–1366PubMedCrossRefGoogle Scholar
  16. Golumbek PT et al. (1991): Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713–716PubMedCrossRefGoogle Scholar
  17. Hershfield MS, Buckley RH, Greenberg ML, et al. (1987): Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 16: 589–596CrossRefGoogle Scholar
  18. Heyman RA, Borrelli E, Lesley J, et al. (1989) Thymidine kinase obliteration: creation of transgenic mice with controlled immunodeficiency. Proc Natl Acad Sci USA 86: 2698–2702PubMedCrossRefGoogle Scholar
  19. Hirschhorn R (1983): Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase: overview, genetic heterogeneity and therapy. Birth Defect 19: 73–81Google Scholar
  20. Kantoff PW, Kohn DB Mitsuya H, et al. (1986): Correction of adenosine deami-nase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 83: 6563–6567PubMedCrossRefGoogle Scholar
  21. Miller AD (1992): Human gene therapy comes of age. Nature 357: 455–460PubMedCrossRefGoogle Scholar
  22. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46: 5276–5281PubMedGoogle Scholar
  23. Oldfield EH, Culver KW, Ram Z, Blaese RM (1993): A clinical protocol: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39–69PubMedCrossRefGoogle Scholar
  24. O’Reilly RJ, Keever CA, Small TN, Brochstein J (1989): The use of HLA-non- identical T-cell-depleted marrow transplants for the correction of severe combined immunodeficiency disease. Immunodeficiency Rev 1: 273–309Google Scholar
  25. Orkin SH, Daddona PE, Shewach DS, et al. (1983): Molecular cloning of human adenosine deaminase gene sequences. J Biol Chem 158: 12753–12756Google Scholar
  26. Osborne WRA, Hock RA, Kaleko M, Miller AD (1990): Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors. Human Gene Ther 1: 31–41CrossRefGoogle Scholar
  27. Panis Y, Caruso M, Houssin D, et al (1992): Treatment of experimental hepatic tumors with in vivo transfer of a suicide gene in the rat. C R Acad Sci Paris 315: 541–544PubMedGoogle Scholar
  28. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield, EH (1993): In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats. Cancer Res 53: 83–88PubMedGoogle Scholar
  29. Rosenberg SA, Aebersold P, Cornetta K, et al. (1990): Gene transfer into humans- Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570–578PubMedCrossRefGoogle Scholar
  30. Short MP, Choi, JK, Lee A, et al. (1990): Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neuroscience Res 27: 427–433CrossRefGoogle Scholar
  31. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J (1993): Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA. Science 259: 94–97PubMedCrossRefGoogle Scholar
  32. Valentine WN, Paglia DE, Tartaglia AP, Gilsanz F (1977): Hereditary hemolytic anemia with increased adenosine deaminase (45–70 fold) and decreased adenosine triphosphates. Science 195: 783PubMedCrossRefGoogle Scholar
  33. Valerio D, Duyvesteyn MGC, Meera Khan P, et al. (1983): Isolation of cDNA clones for human adenosine deaminase. Gene 25: 231–240PubMedCrossRefGoogle Scholar
  34. Wiginton DA, Adrian GS, Friedman RL, et al. (1983): Cloning of cDNA sequences of human adenosine deaminase. Proc Natl Acad Sci USA 80: 7481–7485PubMedCrossRefGoogle Scholar
  35. Weisacker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M (1981): The 9L rat brain tumor model: Description and application of the model. J Neurol 224: 183–192CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1994

Authors and Affiliations

  • Kenneth W. Culver
  • R. Michael Blaese

There are no affiliations available

Personalised recommendations